Skip to main content
. 2022 Jun 15;23(12):6689. doi: 10.3390/ijms23126689

Figure 1.

Figure 1

Molecular pathway depicting TGF-β-induced cutaneous fibrosis. The small-molecule inhibitor galunisertib prevents the phosphorylation of the intracellular domain on the TGF-βR-1/ALK5 serine-threonine kinase, thereby preventing downstream Smad2/3 signaling and nuclear translocation, resulting in the attenuation of fibrotic phenotypes.